Fox Run Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Fox Run Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,913	Closed	-$411K	–	987
2026 Q1	$411K	Buy	+14,913	New	+$381K	0.07%	523
2025 Q2	–	Sell	-11,111	Closed	-$160K	–	922
2025 Q1	$160K	Buy	+11,111	New	+$182K	0.02%	823

Fox Run Management's CNTA Position: Q2 2026 in Review

Fox Run Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 14,913 shares — an estimated $411K sold.

Fox Run Management first reported a position in CNTA in Q1 2025 and held it in 2 quarters. The position peaked at $411K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Fox Run Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 14,913 Centessa Pharmaceuticals shares in Q2 2026, an estimated $411K.
Fox Run Management first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 2 quarters.
Fox Run Management's Centessa Pharmaceuticals position peaked at $411K in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.